enGene to Discuss Surfactant-Enhanced Bladder Cancer Therapy in KOL Webinar
Event summary
- enGene Therapeutics to host KOL webinar on October 15, 2026, at 10:00 AM ET.
- Focus on preclinical data supporting surfactant bladder rinse plus detalimogene for BCG-unresponsive NMIBC.
- Two KOLs from Colorado Urology to review clinical case studies and treatment considerations.
- Live Q&A session to follow formal presentations.
The big picture
enGene's webinar underscores the strategic shift toward surfactant-enhanced gene therapies for bladder cancer, a high-unmet-need indication. The focus on BCG-unresponsive NMIBC with CIS highlights the company's push to address a challenging patient population. The involvement of KOLs from Colorado Urology signals an effort to build clinical credibility ahead of potential regulatory milestones.
What we're watching
- Clinical Validation
- How the surfactant-enhanced detalimogene therapy performs in ongoing LEGEND trial.
- Regulatory Pathway
- Whether preclinical data will support accelerated approval pathways.
- Market Positioning
- The pace at which enGene can differentiate itself in the NMIBC treatment landscape.
Related topics